Cell fusion is a potent inducer of aneuploidy and drug resistance in tumor cell/ normal cell hybrids

Critical Reviews in Oncogenesis

Volumn 18, Issue 1-2, 2013, Pages 97-113

  Berndt, Benjamin ^a   Zänker, Kurt S ^a   Dittmar, Thomas ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Adult stem cells; Breast cancer; Cell fusion; Drug resistance; Hybrid cells; Tumor progression

Indexed keywords

ALVESPIMYCIN; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 1B1; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOXORUBICIN; DOXORUBICIN DERIVATIVE; ETOPOSIDE; GEFITINIB; MICRORNA; MICRORNA 125B; PACLITAXEL; PROTEIN BAX; PROTEIN MAD2; TAMOXIFEN; TEMOZOLOMIDE; VERAPAMIL;

ADULT STEM CELL; ANEUPLOIDY; ARTICLE; BLADDER CARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CELL CLONE; CELL FUSION; CELL STRAIN V 79; CELL STRESS; CHROMOSOMAL INSTABILITY; CHROMOSOME NUMBER; CHROMOSOME SEGREGATION; GENE EXPRESSION; GENE REPRESSION; GENOMIC INSTABILITY; GLIOBLASTOMA; HETEROKARYON; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HYBRID CELL; INTESTINE TUMOR; MACROPHAGE; MALIGNANT TRANSFORMATION; MELANOMA CELL; MESENCHYMAL STEM CELL; MULTIDRUG RESISTANCE; MYELOMA CELL; NONHUMAN; NUCLEAR ENERGY; OSTEOCLAST; PHENOTYPE; PLOIDY; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; STEM CELL; TUMOR CELL; TUMOR GROWTH; UPREGULATION;

ADULT STEM CELLS; ANEUPLOIDY; APOPTOSIS; CELL FUSION; CLONE CELLS; DRUG RESISTANCE, NEOPLASM; GENOMIC INSTABILITY; HUMANS; HYBRID CELLS;

EID: 84875310730     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v18.i1-2.60     Document Type: Article

References (114)

1. Dittmar T, Zänker KS. Cell Fusion in Health and Disease. Dordrecht, The Netherlands: Springer. 2011.
2. Gadella BM, Evans JP. Membrane fusions during Mammalian fertilization. Adv Exp Med Biol. 2011;713:65-80.
3. Huppertz B, Gauster M. Trophoblast fusion. Adv Exp Med Biol. 2011;713:81-95.
4. Sanges D, Lluis F, Cosma MP. Cell-fusion-mediated reprogramming: pluripotency or transdifferentiation? Implications for regenerative medicine. Adv Exp Med Biol. 2011;713:137-59.
5. Simionescu A, Pavlath GK. Molecular mechanisms of myoblast fusion across species. Adv Exp Med Biol. 2011;713:113-35.
6. Alvarez-Dolado M, Martinez-Losa M. Cell fusion and tissue regeneration. Adv Exp Med Biol. 2011;713:161-75.
7. Backovic M, Jardetzky TS. Class III viral membrane fusion proteins. Adv Exp Med Biol. 2011;714:91-101.
8. Powell AE, Anderson EC, Davies PS, Silk AD, Pelz C, Impey S, Wong MH. Fusion between Intestinal epithelial cells and macrophages in a cancer context results in nuclear reprogramming. Cancer Res. 2011;71:1,497-505.
9. Rizvi AZ, Swain JR, Davies PS, Bailey AS, Decker AD, Willenbring H, Grompe M, Fleming WH, Wong MH. Bone marrow-derived cells fuse with normal and transformed intestinal stem cells. Proc Natl Acad Sci U S A. 2006;103:6,321-5.
10. Goldenberg DM, Bhan RD, Pavia RA. In vivo human-hamster somatic cell fusion indicated by glucose 6-phosphate dehydrogenase and lactate dehydrogenase profiles. Cancer Res. 1971;31:1,148-52.
11. Goldenberg DM, Pavia RA, Tsao MC. In vivo hybridisation of human tumour and normal hamster cells. Nature. 1974;250:649-51.
12. Jacobsen BM, Harrell JC, Jedlicka P, Borges VF, Varella-Garcia M, Horwitz KB. Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium. Cancer Res. 2006;66:8,274-9.
13. Busund LT, Killie MK, Bartnes K, Seljelid R. Spontaneously formed tumorigenic hybrids of Meth A sarcoma and macrophages grow faster and are better vascularized than the parental tumor. Int J Cancer. 2002;100:407-13.
14. Rachkovsky M, Sodi S, Chakraborty A, Avissar Y, Bolognia J, McNiff JM, Platt J, Bermudes D, Pawelek J. Melanoma x macrophage hybrids with enhanced metastatic potential. Clin Exp Metastasis. 1998;16:299-312.
15. Lu X, Kang Y. Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants. Proc Natl Acad Sci U S A. 2009;106:9,385-90.
16. Duelli DM, Lazebnik YA. Primary cells suppress oncogene-dependent apoptosis. Nat Cell Biol. 2000;2:859-62.
17. Duelli D, Lazebnik Y. Cell fusion: a hidden enemy? Cancer Cell. 2003;3:445-8.
18. Dittmar T, Schwitalla S, Seidel J, Haverkampf S, Reith G, Meyer-Staeckling S, Brandt BH, Niggemann B, Zanker KS. Characterization of hybrid cells derived from spontaneous fusion events between breast epithelial cells exhibiting stem-like characteristics and breast cancer cells. Clin Exp Metastasis. 2011;28:75-90.
19. Nagler C, Hardt C, Zänker KS, Dittmar T. Co-cultivation of murine BMDCs with 67NR mouse mammary carcinoma cells give rise to highly drug resistant hybrid cells. Cancer Cell International. 2011;11:21-34.
20. Zhou X, Platt JL. Molecular and cellular mechanisms of Mammalian cell fusion. Adv Exp Med Biol. 2011;713:33-64.
21. Duelli D, Lazebnik Y. Cell-to-cell fusion as a link between viruses and cancer. Nat Rev Cancer. 2007;7:968-76.
22. Fang TC, Alison MR, Cook HT, Jeffery R, Wright NA, Poulsom R. Proliferation of bone marrow-derived cells contributes to regeneration after folic acid-induced acute tubular injury. J Am Soc Nephrol. 2005;16:1,723-32.
23. Johansson CB, Youssef S, Koleckar K, Holbrook C, Doyonnas R, Corbel SY, Steinman L, Rossi FM, Blau HM. Extensive fusion of haematopoietic cells with Purkinje neurons in response to chronic inflammation. Nat Cell Biol. 2008;10:575-83.
24. Nygren JM, Liuba K, Breitbach M, Stott S, Thoren L, Roell W, Geisen C, Sasse P, Kirik D, Bjorklund A, Nerlov C, Fleischmann BK, Jovinge S, Jacobsen SE. Myeloid and lymphoid contribution to non-haematopoietic lineages through irradiation-induced heterotypic cell fusion. Nat Cell Biol. 2008;10:584-92.
25. Davies PS, Powell AE, Swain JR, Wong MH. Inflammation and proliferation act together to mediate intestinal cell fusion. PLoS ONE. 2009;4:e6530.
26. Alvarez-Dolado M, Pardal R, Garcia-Verdugo JM, Fike JR, Lee HO, Pfeffer K, Lois C, Morrison SJ, Alvarez-Buylla A. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature. 2003;425:968-73.
27. Camargo FD, Finegold M, Goodell MA. Hematopoietic myelomonocytic cells are the major source of hepatocyte fusion partners. J Clin Invest. 2004;113:1,266-70.
28. Vassilopoulos G, Wang PR, Russell DW. Transplanted bone marrow regenerates liver by cell fusion. Nature. 2003;422:901-4.
29. Wang X, Willenbring H, Akkari Y, Torimaru Y, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, Olson S, Grompe M. Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature. 2003;422:897-901.
30. Willenbring H, Bailey AS, Foster M, Akkari Y, Dorrell C, Olson S, Finegold M, Fleming WH, Grompe M. Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. Nat Med. 2004;10:744-8.
31. Spees JL, Olson SD, Ylostalo J, Lynch PJ, Smith J, Perry A, Peister A, Wang MY, Prockop DJ. Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma. Proc Natl Acad Sci U S A. 2003;100:2,397-402.
32. Ferrand J, Noel D, Lehours P, Prochazkova-Carlotti M, Chambonnier L, Menard A, Megraud F, Varon C. Human bone marrow-derived stem cells acquire epithelial characteristics through fusion with gastrointestinal epithelial cells. PLoS ONE. 2011;6:e19569.
33. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-45.
34. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1,650-9.
35. Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH, Yang PC. Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol. 2005;23:953-64.
36. Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, Pixley FJ, Stanley ER, Segall JE, Condeelis JS. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 2005;65:5,278-83.
37. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996;56:4,625-9.
38. Lewis C, Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol. 2005;167:627-35.
39. Shih JY, Yuan A, Chen JJW, Yang PC. Tumor-associated macrophage: its role in cancer invasion and metastasis. J Cancer Mol. 2006;2:101-6.
40. Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, Nishioka Y, Sone S, Kuwano M. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int J Cancer. 2000;85:182-8.
41. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condeelis J. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004;64:7,022-9.
42. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, Wei S, Krzysiek R, Durand-Gasselin I, Gordon A, Pustilnik T, Curiel DT, Galanaud P, Capron F, Emilie D, Curiel TJ. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med. 2001;7:1,339-46.
43. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR, Wang TC. Gastric cancer originating from bone marrow-derived cells. Science. 2004;306:1568-71.
44. Aichel O. Über Zellverschmelzung mit quantitativ abnormer Chromosomenverteilung als Ursache der Geschwulstbildung. In: Roux W, editor. Vorträge und Aufsätze über Entwicklungsmechanik der Organismen. Leipzig, Germany: Wilhelm Engelmann;1911:1-115.
45. Schmidt A, Weber OF. In memoriam of Rudolf Virchow: a historical retrospective including aspects of inflammation, infection and neoplasia. Contrib Microbiol. 2006;13:1-15.
46. Boveri T. Zur Frage der Entstehung Maligner Tumoren: Gustav Fischer Verlag, Jena, Germany 1914.
47. von Hansemann D. Virchows Arch Pathol Anat. 1890;119:299-326.
48. Goldenberg DM. [On the progression of malignity: a hypothesis]. Klin Wochenschr. 1968;46:898-9.
49. Mekler LB, Drize OB, Osechinskii IV, Shliankevich MA. [Transformation of a normal differentiated cell of an adult organism, induced by the fusion of this cell with another normal cell of the same organism but with different organ or tissue specificity]. Vestn Akad Med Nauk SSSR. 1971;26:75-80.
50. Mekler LB. [Hybridization of transformed cells with lymphocytes as 1 of the probable causes of the progression leading to the development of metastatic malignant cells]. Vestn Akad Med Nauk SSSR. 1971;26:80-9.
51. Goldenberg DM, Zagzag D, Heselmeyer-Haddad KM, Berroa Garcia LY, Ried T, Loo M, Chang CH, Gold DV. Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells In Vivo. Int J Cancer. 2012:131:49-58.
52. Chakraborty AK, Sousa de Freitas J, Espreafico EM, Pawelek JM. Human monocyte x mouse melanoma fusion hybrids express human gene. Gene. 2001;275:103-6.
53. Duesberg P, Mandrioli D, McCormack A, Nicholson JM. Is carcinogenesis a form of speciation? Cell Cycle. 2011;10:2,100-14.
54. Rachkovsky M, Pawelek J. Acquired melanocyte stimulating hormone-inducible chemotaxis following macrophage fusion with Cloudman S91 melanoma cells. Cell Growth Differ. 1999;10:517-24.
55. Andersen TL, Boissy P, Sondergaard TE, Kupisiewicz K, Plesner T, Rasmussen T, Haaber J, Kolvraa S, Delaisse JM. Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership? J Pathol. 2007;211:10-7.
56. Lu X, Kang Y. Cell fusion as a hidden force in tumor progression. Cancer Res. 2009;69:8,536-9.
57. Hu L, Plafker K, Vorozhko V, Zuna RE, Hanigan MH, Gorbsky GJ, Plafker SM, Angeletti PC, Ceresa BP. Human papillomavirus 16 E5 induces bi-nucleated cell formation by cell-cell fusion. Virology. 2009;384:125-34.
58. Hu L, Ceresa BP. Characterization of the plasma membrane localization and orientation of HPV16 E5 for cell-cell fusion. Virology. 2009;393:135-43.
59. Dittmar T, Nagler C, Schwitalla S, Reith G, Niggemann B, Zanker KS. Recurrence cancer stem cells-made by cell fusion? Med Hypotheses. 2009;73:542-7.
60. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer. 2005;5:899-904.
61. Duncan AW, Hickey RD, Paulk NK, Culberson AJ, Olson SB, Finegold MJ, Grompe M. Ploidy reductions in murine fusion-derived hepatocytes. PLoS Genet. 2009;5:e1000385.
62. Duncan AW, Taylor MH, Hickey RD, Hanlon Newell AE, Lenzi ML, Olson SB, Finegold MJ, Grompe M. The ploidy conveyor of mature hepatocytes as a source of genetic variation. Nature. 2010;467:707-10.
63. Dittmar T, Nagler C, Niggemann B, Zänker KS. The dark side of stem cells: triggering cancer progression by cell fusion. Curr Mol Med. 2012; accepted.
64. Chakraborty AK, Sodi S, Rachkovsky M, Kolesnikova N, Platt JT, Bolognia JL, Pawelek JM. A spontaneous murine melanoma lung metastasis comprised of host x tumor hybrids. Cancer Res. 2000;60:2,512-9.
65. Pawelek J, Chakraborty A, Lazova R, Yilmaz Y, Cooper D, Brash D, Handerson T. Co-opting macrophage traits in cancer progression: a consequence of tumor cell fusion? Contrib Microbiol. 2006;13:138-55.
66. Pawelek JM, Chakraborty AK. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat Rev Cancer. 2008;8:377-86.
67. Miller FR, Mohamed AN, McEachern D. Production of a more aggressive tumor cell variant by spontaneous fusion of two mouse tumor subpopulations. Cancer Res. 1989;49:4,316-21.
68. Luo C, Johnston PJ, MacPhail SH, Banath JP, Oloumi A, Olive PL. Cell fusion studies to examine the mechanism for etoposide resistance in Chinese hamster V79 spheroids. Exp Cell Res. 1998;243:282-9.
69. Yang JY, Ha SA, Yang YS, Kim JW. p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance. BMC Cancer. 2010;10:388.
70. Frank NY, Pendse SS, Lapchak PH, Margaryan A, Shlain D, Doeing C, Sayegh MH, Frank MH. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem. 2003;278:47,156-65.
71. Hembruff SL, Laberge ML, Villeneuve DJ, Guo B, Veitch Z, Cecchetto M, Parissenti AM. Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance. BMC Cancer. 2008;8:318.
72. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219-34.
73. Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD, McLeod HL, Synold TW. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 2007;7:362-5.
74. Zheng T, Wang J, Chen X, Liu L. Role of microRNA in anticancer drug resistance. Int J Cancer. 2010;126:2-10.
75. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9:102-14.
76. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, Pogribny IP. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 2008;7:2,152-9.
77. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76:582-8.
78. Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol. 2009;75:1,374-9.
79. To KK, Zhan Z, Litman T, Bates SE. Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol. 2008;28:5,147-61.
80. Jeon HM, Sohn YW, Oh SY, Kim SH, Beck S, Kim S, Kim H. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res. 2011;71:3,410-21.
81. Shi L, Zhang S, Feng K, Wu F, Wan Y, Wang Z, Zhang J, Wang Y, Yan W, Fu Z, You Y. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to. Int J Oncol. 2012;40:119-29.
82. Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol. 2012;81:103-22.
83. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11:849-64.
84. Wang Y, Fan H, Zhou B, Ju Z, Yu L, Guo L, Han J, Lu S. Fusion of human umbilical cord mesenchymal stem cells with esophageal cells. Int J Oncol. 2012;40:370-7.
85. Fritz V, Jorgensen C. Mesenchymal stem cells: an emerging tool for cancer targeting and therapy. Curr Stem Cell Res Ther. 2008;3:32-42.
86. Wong RS. Mesenchymal stem cells: angels or demons? J Biomed Biotechnol. 2011;2011: 459,510-8.
87. Heim S, Mitelman F. Cancer Cytogenetics. Second ed. New York: Wiley-Liss; 1995.
88. Mertens F, Johansson B, Hoglund M, Mitelman F. Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res. 1997;57:2,765-80.
89. Duesberg P, Li R, Rasnick D, Rausch C, Willer A, Kraemer A, Yerganian G, Hehlmann R. Aneuploidy precedes and segregates with chemical carcinogenesis. Cancer Genet Cytogenet. 2000;119:83-93.
90. Duesberg P, Rasnick D. Aneuploidy, the somatic mutation that makes cancer a species of its own. Cell Motil Cytoskeleton. 2000;47:81-107.
91. Duesberg P, Rausch C, Rasnick D, Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci USA. 1998; 95: 13,692-7.
92. Sotillo R, Hernando E, Diaz-Rodriguez E, Teruya-Feldstein J, Cordon-Cardo C, Lowe SW, Benezra R. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell. 2007;11:9-23.
93. Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell. 2007;11:25-36.
94. Sheltzer JM, Blank HM, Pfau SJ, Tange Y, George BM, Humpton TJ, Brito IL, Hiraoka Y, Niwa O, Amon A. Aneuploidy drives genomic instability in yeast. Science. 2011;333:1,026-30.
95. Li R, Sonik A, Stindl R, Rasnick D, Duesberg P. Aneuploidy versus gene mutation hypothesis of cancer: recent study claims mutation, but is found to support aneuploidy. Proc Natl Acad Sci USA. 2000;97:3,236-41.
96. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-7.
97. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9,339-44.
98. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-11.
99. Li F, Tiede B, Massague J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 2007;17:3-14.
100. Croker AK, Allan AL. Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med. 2008;12:374-90.
101. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 2009;(8B):2236.52.
102. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313-23.
103. Nagler C, Zanker KS, Dittmar T. Cell Fusion, Drug Resistance and Recurrence CSCs. Adv Exp Med Biol. 2011;714:173-82.
104. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 2008;26:2,839-45.
105. Rich JN. Cancer stem cells in radiation resistance. Cancer Res. 2007;67:8,980-4.
106. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275-84.
107. Shervington A, Lu C. Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest. 2008;26:535-42.
108. Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood. 2006;107:431-34.
109. Jones RJ, Matsui WH, Smith BD. Cancer stem cells: are we missing the target? J Natl Cancer Inst. 2004;96:583-85.
110. Dean M. Cancer stem cells: redefining the paradigm of cancer treatment strategies. Mol Interv. 2006;6:140-8.
111. Galmozzi E, Facchetti F, La Porta CA. Cancer stem cells and therapeutic perspectives. Curr Med Chem. 2006;13:603-7.
112. Trumpp A, Wiestler OD. Mechanisms of Disease: cancer stem cells-targeting the evil twin. Nat Clin Pract Oncol. 2008;5:337-47.
113. Blagosklonny MV. Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle. 2005;4:1,693-8.
114. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ, Lee EY. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 2008;68:3,243-50.